Michael Fredericson, MD
Orthopedic Surgery · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fredericson’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G67096 · Current
Licensed to practise in California · since 1989 · expires 2027-02-28 · New York Medical College, New York.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$25,900
Medicare paid this office $25,900 for 172 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nerve test | 45 | $5,545 | $123 |
| Nerve test | 28 | $4,864 | $168 |
| Muscle electrical test | 91 | $4,490 | $39 |
| Return visit (30+ min) | 20 | $2,948 | $89 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 43 | $2,838 | $52 |
See all 8 services
| Nerve test | 45 | $5,545 | $123 |
| Nerve test | 28 | $4,864 | $168 |
| Muscle electrical test | 91 | $4,490 | $39 |
| Return visit (30+ min) | 20 | $2,948 | $89 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 43 | $2,838 | $52 |
| Nerve test | 16 | $1,902 | $119 |
| New patient visit (45+ min) | 11 | $1,062 | $97 |
| Aspiration and/or injection of fluid from large joint | 13 | $644 | $40 |
Who their Medicare patients are
172 Original Medicare patients in 2024. Average age 74 · Under 65 9% · 85 and older 6% · Women 52% · Also on Medicaid 19% · Health risk score 1.32. Above the middle of the specialty; the typical orthopedic surgery clinician is at 1.13.
Conditions among them: High blood pressure 65% · Coronary heart disease 34% · Diabetes 24% · Depression 24% · Chronic kidney disease 21% · Cancer 16% · Atrial fibrillation 16% · Heart failure 15% · COPD 15% · Stroke 6%.
The office billed $136,383, Medicare allowed $34,488 and paid $25,900; for 358 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 172 | 358 | 74 | 1.32 | $136,383 | $25,900 |
| 2023 | 175 | 347 | 73 | 1.21 | $142,748 | $26,881 |
| 2022 | 173 | 326 | 73 | 0.94 | $82,237 | $17,446 |
| 2021 | 155 | 294 | 71 | 1.07 | $56,323 | $14,059 |
| 2020 | 122 | 246 | 71 | 1.01 | $62,944 | $11,191 |
| 2019 | 154 | 331 | 71 | 1.14 | $81,664 | $19,278 |
| 2018 | 172 | 402 | 71 | 1.23 | $103,250 | $27,875 |
| 2017 | 158 | 367 | 71 | 1.27 | $218,124 | $27,496 |
| 2016 | 161 | 417 | 70 | 1.24 | $362,727 | $32,215 |
| 2015 | 145 | 431 | 71 | 1.01 | $300,427 | $32,157 |
| 2014 | 127 | 358 | 71 | 1.34 | $267,455 | $27,359 |
| 2013 | 199 | 502 | 70 | 1.37 | $371,473 | $37,840 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Nerve test | 45 | $6,405 | $139 |
| Nerve test | 30 | $4,953 | $165 |
| Muscle electrical test | 93 | $4,476 | $41 |
| Return visit (30+ min) | 26 | $3,163 | $90 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 39 | $2,140 | $50 |
| New patient visit (45+ min) | 17 | $1,829 | $108 |
| Nerve test | 17 | $1,735 | $102 |
| Ultrasonic guidance for needle placement | 13 | $355 | $27 |
2022: 9 services
| Muscle electrical test | 76 | $3,754 | $42 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 49 | $2,685 | $51 |
| Return visit (30+ min) | 25 | $2,177 | $78 |
| New patient visit (45+ min) | 18 | $2,159 | $120 |
| Nerve test | 29 | $1,858 | $64 |
| Nerve test | 18 | $1,251 | $69 |
| Nerve test | 28 | $808 | $29 |
| Aspiration and/or injection of fluid from large joint | 13 | $671 | $42 |
| Ultrasonic guidance for needle placement | 16 | $413 | $26 |
2021: 8 services
| Muscle electrical test | 93 | $3,970 | $41 |
| Nerve test | 33 | $1,966 | $60 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 22 | $1,335 | $51 |
| Return visit (30+ min) | 14 | $1,288 | $86 |
| Nerve test | 44 | $1,210 | $27 |
| Nerve test | 16 | $1,003 | $63 |
| Aspiration and/or injection of fluid from large joint | 11 | $456 | $38 |
| Ultrasonic guidance for needle placement | 14 | $420 | $28 |
2020: 6 services
| Muscle electrical test | 79 | $3,387 | $38 |
| Nerve test | 34 | $2,009 | $57 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 28 | $1,727 | $52 |
| Return visit (30+ min) | 14 | $1,236 | $69 |
| Nerve test | 31 | $719 | $23 |
| Nerve test | 13 | $639 | $49 |
2019: 8 services
| Muscle electrical test | 91 | $4,103 | $40 |
| Nerve test | 43 | $3,497 | $81 |
| Nerve test | 22 | $2,354 | $107 |
| Nerve test | 23 | $2,086 | $91 |
| Return visit (30+ min) | 28 | $2,062 | $62 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 30 | $1,800 | $53 |
| Aspiration and/or injection of fluid from large joint | 12 | $609 | $36 |
| Ultrasonic guidance for needle placement | 14 | $377 | $25 |
2018: 10 services
| Nerve test | 40 | $5,850 | $143 |
| Muscle electrical test | 85 | $4,143 | $40 |
| Nerve test | 24 | $3,964 | $165 |
| Return visit (30+ min) | 51 | $3,900 | $67 |
| Nerve test | 22 | $2,616 | $114 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 30 | $1,725 | $52 |
| New patient visit (45+ min) | 12 | $1,157 | $96 |
| Aspiration and/or injection of fluid from large joint | 15 | $904 | $41 |
| Ultrasonic guidance for needle placement | 30 | $867 | $28 |
| Injection into tendon at attachment to bone or muscle | 19 | $599 | $32 |
2017: 9 services
| Nerve test | 57 | $7,954 | $137 |
| Muscle electrical test | 96 | $4,618 | $39 |
| Nerve test | 23 | $3,874 | $168 |
| Return visit (30+ min) | 50 | $3,789 | $68 |
| Nerve test | 13 | $1,499 | $115 |
| Long return visit (40+ min) | 14 | $1,388 | $99 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 20 | $1,114 | $53 |
| New patient visit (45+ min) | 11 | $805 | $73 |
| New patient visit (30+ min) | 11 | $743 | $68 |
2016: 8 services
| Nerve test | 60 | $8,999 | $143 |
| Muscle electrical test | 113 | $6,788 | $42 |
| Nerve test | 34 | $5,591 | $155 |
| Return visit (30+ min) | 42 | $3,525 | $69 |
| Nerve test | 21 | $2,582 | $123 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 15 | $854 | $53 |
| New patient visit (30+ min) | 11 | $747 | $68 |
| Short return visit (20+ min) | 14 | $639 | $46 |
2015: 10 services
| Nerve test | 55 | $7,865 | $138 |
| Muscle electrical test | 96 | $4,730 | $42 |
| Return visit (30+ min) | 52 | $4,440 | $68 |
| Nerve test | 30 | $3,109 | $104 |
| Long return visit (40+ min) | 20 | $2,284 | $99 |
| Nerve test | 13 | $2,115 | $163 |
| Short return visit (20+ min) | 46 | $2,093 | $46 |
| New patient visit (45+ min) | 20 | $1,900 | $95 |
| New patient visit (30+ min) | 12 | $815 | $68 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 12 | $742 | $57 |
2014: 6 services
| Nerve test | 63 | $8,890 | $141 |
| Muscle electrical test | 95 | $4,501 | $42 |
| Return visit (30+ min) | 54 | $4,269 | $69 |
| Nerve test | 25 | $2,801 | $112 |
| Short return visit (20+ min) | 35 | $1,594 | $46 |
| New patient visit (30+ min) | 18 | $1,216 | $68 |
2013: 10 services
| Nerve test | 61 | $10,364 | $167 |
| Muscle electrical test | 108 | $5,217 | $33 |
| Return visit (30+ min) | 63 | $4,566 | $62 |
| Nerve test | 32 | $4,504 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $3,168 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,743 | $119 |
| Nerve test | 21 | $2,471 | $118 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,668 | $39 |
| New patient visit (45+ min) | 14 | $1,367 | $98 |
| New patient visit (30+ min) | 11 | $726 | $66 |
Money from drug and device companies
$750 in 2025
| 2025 | 1 | 1 | $750 | $750 |
| 2023 | 1 | 1 | $2,922 | $2,922 |
| 2019 | 2 | 2 | $10,620 | $10,620 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ipsen Pharma SAS | Dysport | $750 | 1 payment
|
See the published payment
| Ipsen Pharma SAS | Consulting · 2025-05-13 | Dysport | $750 |
See earlier years (2023, 2019)
2023: $2,922
| Merz Pharmaceuticals | Xeomin | $2,922 | 1 payment
|
2019: $10,620
| Ipsen Bioscience | Dysport | $9,000 | 1 payment
|
| Ipsen Biopharmaceuticals | Dysport | $1,620 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ipsen Biopharmaceuticals, Inc · Can Dysport Injection Reduce Pain and Patellar Maltracking in Patients With Chronic Patellofemoral Pain Syndrome · 2020 | Their institution | $10,102 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1760538110
- Licence
- CA G67096California G67096: Current · expires 2027-02-28
- Trained
- New York Medical College, 1988
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 208100000X (208100000X); Federal specialty code 2081S0010X (2081S0010X)
- Mailing address
- 300 Pasteur Dr, Edwards R105 Mc 5341, Stanford, CA, 94305
- NPI first listed
- 2007-01-26
- NPI last updated
- 2024-05-06
- NPI record certified
- 2024-05-06
This is when the NPI record was last certified, not a medical board exam.